NO REQUIREMENT TO REPORT NALTREXONE: Recently, the Arizona Board of Pharmacy has received many questions regarding the reporting requirements of opioid antagonists to the CSPMP. The questions stem from part of Senate Bill 1087 focusing on ARS 36-2608. The intent of this language was to require naloxone dispensations to be reported to the CSPMP as well as any future fast-acting emergency opioid antagonists. At this time, there is no requirement to report naltrexone or any full opioid antagonists to the CSPMP for the maintenance of substance use disorder. Again, please only report naloxone at this time.
ANNOUNCEMENT - NEW REPORTING STANDARD: Effective November 01, 2021, the Arizona CSPMP will be adopting the ASAP 4.2B standard of reporting. Version 4.2B brings needed changes to improve the quality and scope of the data reported to the CSPMP. You can find additional information by accessing the "DATA SUBMISSION GUIDE 4.2B - INFO" tab below.
REPORTING WAIVERS: The Arizona Board of Pharmacy decided in its March 22, 2017 meeting to no longer accept waivers for PMP reporting. If your pharmacy has an active DEA number, an active AZ pharmacy permit, and is not limited to veterinary dispensing, it is required to submit a daily report, including zero reports, for controlled substances II-V. To prevent violation of A.R.S. § 36-2608, Reporting Requirements, please register for a PMP Clearinghouse account and begin uploading your schedule II-V dispensations immediately!
ASAP 4.2 DATA SUBMISSION GUIDE: The current Data Submission Guide (DSG) can be found below by clicking on the "Data Submission Guide" tab. The DSG explains the process to register and transmit data to the Arizona PMP via Appriss’s PMP Clearinghouse. Please note that version 4.2B will be adopted on November 01, 2021.
TECHNICAL SUPPORT - If you have any questions or concerns about the data submission process, please contact Appriss Technical Support directly at 1-855-929-4767. Technical Support is available 24 hours a day, 7 days a week.